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Recent studies have generated interest in the function of human adenovirus serotype 5 (HAdV-
5) hexon: factor X (FX) binding and subsequent hepatocyte transduction and interaction with the
immune system. Here, we retargeted adenovirus serotype 5 vectors, ablated for FX interaction,
by replacing amino acids in hexon HVR7 with RGD-4C or inserting the peptide into the fibre HI
loop. These genetic modifications in the capsid were compatible with virus assembly, and could
efficiently retarget transduction of the vector via the avb3/5 integrin-mediated pathway, but did
not alter immune recognition by pre-existing human neutralizing anti-HAdV-5 antibodies or by
natural antibodies in mouse serum. Thus, FX-binding-ablated HAdV-5 can be retargeted but
remain sensitive to immune-mediated attack. These findings further refine HAdV-5-based vectors
for human gene therapy and inform future vector development.
Adenoviral (Ad)-based vectors, particularly those based on
human adenovirus serotype 5 (HAdV-5) are widely used
clinically and experimentally. In vitro, and in local in vivo
applications, HAdV-5 transduces cells via the human cox-
sackie and adenovirus receptor (hCAR) (Bergelson et al.,
1997; Tomko et al., 1997). Our research has focussed on the
use of adenoviral vectors as a tool for ex vivo manipulation
of coronary artery bypass material to overexpress anti-
proliferative genes (e.g. TIMP-3, p53) in coronary artery
vascular smooth muscle cells (VSMCs), to prevent their
migration, proliferation and formation of a neointimal
lesion, and ultimately graft reocclusion and failure following
grafting (George et al., 2011). A significant limitation in this
strategy is that VSMCs express a very low level of CAR and
are thus refractory to transduction (Parker et al., 2013),
necessitating high input titres of HAdV-5 to achieve thera-
peutic levels of transgene expression. For systemic in vivo
applications, HAdV-5 efficiently and selectively transduces
hepatocytes (Huard et al., 1995) in a process mediated
through the engagement of the blood coagulation factor X
(FX) with the hypervariable regions (HVRs) of the HAdV-5
hexon protein (Hofherr et al., 2008; Kalyuzhniy et al., 2008;
Waddington et al., 2008). Through selective modification of
the HVRs, we previously generated a vector (HAdV-5T*)
devoid of FX interactions and consequently hepatocyte
transduction by introducing point mutations in key FX-
interacting amino acids of the hexon protein HVR, namely
T270P and E271G (HVR5) and I421G, T423N, E454S,
L426Y and E451Q (all in HVR7) (Alba et al., 2009). Con-
versely, it has been reported that FX may actually offer a
protective role in gene delivery, by shielding HAdV-5 from
immune-mediated attack by natural IgM and the classical
complement system (Xu et al., 2013), which interact with
HVRs, neutralizing the virus (Ma et al., 2015). The specific
amino acids responsible for immune recognition remain
unknown, and the impact in humans remains unconfirmed.
Incorporation of FX-binding HVRs from HAdV-5 into
HAdV-26 (non-FX-binding Ad serotype) instilled liver
transduction to this vector (Ma et al., 2015), reiterating the
importance of FX in determining viral hepatic transduction.
Therefore, retargeting of FX-ablated virus remains an area
of interest for improving safety and efficacy of gene therapy
vectors.
In this study, we evaluate optimal locations compatible for
inserting targeting peptides within the HAdV-5T* vector.
Previous studies identified the fibre HI loop as viable for
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peptide incorporation for retargeting in vitro and in vivo
(Krasnykh et al., 1998; Dmitriev et al., 1998; Reynolds et al.,
1999). Furthermore, the incorporation of RGD into HAdV-
5 HVR5 was shown to result in increased transduction in
non-permissive VSMCs using a non-modified HAdV-
5 vector with high background hepatocyte transduction
(Vigne et al., 1999). Here, three locations were selected for
peptide incorporation: fibre HI loop (after aa 543G), and
hexon HVRs 5 and 7 (Fig. 1a–d). We selected the RGD-4C
(CDCRGDCFC) peptide to test retargeting because it effi-
ciently binds to avb3 and avb5 integrins expressed on many
cell types, including endothelial cells (Zitzmann et al., 2002).
This peptide has previously been widely used for adenoviral
retargeting studies (Pasqualini et al., 1997; Dmitriev et al.,
1998). The RGD-4C peptide was inserted into the HVRs
with (designated ‘R’ for replacement) or without (designated
‘I’ for insertion) replacement of amino acids upstream of aa
272C (in HVR5) or 432K (in HVR7), whilst replacements
involved removal of aa 272A–280L or 427T–435Q with
simultaneous insertion of the peptide (Fig. 1c, d).
RGD-4C was cloned in modified shuttle plasmids contain-
ing the T* modified sequence (Fig. 1b) (Alba et al., 2009) or
fibre HI loop (Fig. 1d) (Alba et al., 2010). Vectors were lin-
earized and electroporated into BJ5183 bacteria cells with
digested pAd5CMVlacZ for homologous recombination.
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Fig. 1. RGD-4C peptide placement in HAdV-5T* and quality control analysis of purified viruses. (a) Hexon trimer protein;
arrows indicate RGD-4C insertion sites in HVR5 (orange) or HVR7R (blue). (b) HAdV-5 hexon amino acid sequence; HVR5
and HVR7 are highlighted in grey; T* point mutations are marked with an asterisks (*). The amino acids removed for generation
of RGD-4C replacement vectors are designated by dashed lines and the RGD-4C insertion points are indicated by black
arrows. (c) Fibre protein; arrows indicate RGD-4C insertion sites in HI loop (purple). (d) HAdV-5 fibre amino acid sequence;
arrow indicates insertion site of RGD-4C. (e) Details of vector production, indicating preparation in HEK293 cells and infec-
tious titres measured by end-point dilution infection in HEK293 cells, physical titres quantified by micro bicinchoninic acid
assay (microBCA) and nanoparticle-tracking analysis (Nanosight) and the respective VP: p.f.u. ratios for each virus. (f) Analysis
of viral proteins by SDS-PAGE and silver-staining.
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Adenoviral production was performed in HEK293 cells as
described previously (Alba et al., 2009). Peptide insertion in
HAdV-5T*HVR7I proved incompatible with virus assem-
bly, suggesting limitations for peptide insertion within this
locale. Virus generation could be achieved for HAdV-
5T*HVR5I; however, titre assessment indicated very poor
virus particle (VP): p.f.u. ratios (Fig. 1e), again suggesting
that simple insertion strategies within the HVRs appear to
limit viral fitness, and this virus was therefore excluded
from subsequent analysis. All other viruses were successfully
propagated, and verified by sequencing, and quality control
demonstrated consistent, high-quality virus batches, as
assessed by silver-staining, bicinchoninic acid (BCA) assay,
nanoparticle-tracking analysis (NanoSight LM10; Malvern)
and p.f.u. assays (Fig. 1e, f), thus demonstrating amino acid
removal from HVR5 and HVR7 is non-essential for virus
assembly.
Recombinant viruses were evaluated for cell binding and
transduction in av-integrin-positive SKOV3 cells and A549
cells (Guo et al., 2009; Cannistra et al., 1995). Cells were
transduced with HAdV-5, HAdV-5T* and peptide-modified
adenoviral vectors at 50 p.f.u. cell 1, and transduction was
assessed 48 h post-transduction after a 3 h exposure to each
Ad by measuring b-galactosidase activity using the Tropix
Galacton Plus and Tropix Accelerator II kit (Applied Biosys-
tems). Replacement of amino acids in HVR5 with RGD-4C
or its insertion in the HI loop failed to increase cell transduc-
tion compared with HAdV-5 or HAdV-5T*. However,
replacing amino acids in HVR7 (HAdV-5T*HVR7R) with
RGD-4C in the HAdV-5T* background exhibited >10-fold
increase in transduction compared with the parental HAdV-
5T* vector (Fig. 2a, b), validating HVR7 as a candidate site
for targeting peptide insertion. Strategies to improve vascular
tropism for effective gene delivery in coronary artery bypass
graft purposes need to efficiently target VSMCs; therefore we
tested viral transduction in low-passage (passage 2–5) human
saphenous vein (HSV) primary VSMCs, isolated as previ-
ously described (Southgate & Newby, 1990). Using the RGD-
targeted vectors (500 p.f.u. cell 1), we observed a robust six-
fold increase in transduction in HSV VSMC transduced with
HAdV-5T*HVR7R or HAdV-5T*HI loop compared with
HAdV-5 or HAdV-5T*, but not HAdV-5T*HVR5R
(Fig. 2c). This contrasts with previous studies demonstrating
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Fig. 2. Assessment of HAdV-5T* retargeting by cell surface binding and viral transduction in three cell types. Cells were
transduced with HAdV-5, HAdV-5T* and peptide-modified adenoviral vectors (HAdV-5T*HVR5R, HAdV-5T*HVR7R and
HAdV-5T*HI loop) at a concentration of 50 p.f.u. cell 1 for SKOV3 and A549 cells and 500 p.f.u. cell 1 for HSV VSMCs.
(a–c) Transduction was assessed 48 h post-transduction after a 3 h exposure to each HAdV, by measuring b-galactosidase
activity. (d–f) Surface-binding analysis was performed by incubating the HAdV with the cells at 4 C for 1 h and quantifying
cell-bound adenoviral vectors by measuring adenoviral genomes by quantitative PCR as described in Alba et al. (2009). Each
experiment was performed in technical triplicate and repeated three independent times. Mean±SD one-way ANOVA with Bon-
ferroni post-hoc analysis was performed using GraphPad Prism v.5; ***P<0.001.
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insertion of RGD in HVR5 in an otherwiseWTHAdV-5 cap-
sid, which did increase VSMC transduction (Vigne et al.,
1999). This discrepancy could relate to the different RGD
peptide sequence used in each study; our peptide contained
four cysteines (CDCRGDCFC) in contrast to only two in the
previous study (DCRGDCF) (Vigne et al., 1999). Addition-
ally, these differences may relate to conformation alterations
introduced by the specific combination of the FX-binding-
ablating mutations engineered in HVR5 combined with the
RGD peptide incorporation.
Surface binding analysis was performed by incubating the
recombinant vectors with the cells at 4

C for 1 h. DNA was
then isolated using the QIAamp DNA Mini kit (QIAGEN)
and cell-membrane associated viral genomes were quanti-
fied by quantitative PCR as described previously (Alba et al.,
2009). No change in binding was observed for HAdV-
5T*HVR5R in any cell type, compared with HAdV-5T*
(Fig. 2d, e, f), confirming that insertion of peptides within
HVR5 confers little retargeting benefit, whilst significant
increases in cell association were observed for HAdV-
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Fig. 3. Evaluation of the effect of peptide insertion on evasion of neutralizing anti-HAdV-5 immunity. (a) HAdV-5T* and its
derivatives (21010 vp ml 1) were incubated with RPMI-1640 medium, 90% C57BL/6 mouse serum or 90% C57BL/6
mouse serum pre-incubated with 40 µg ml 1 X-bp, for 30min at 37 C. Virus suspensions were diluted 200-fold in serum-free
medium and 100 µl was added to SKOV3 cells for 2 h at 37 C before being replaced with RPMI-1640 medium with 2% FCS.
Transgene expression was quantified 16 h post-transduction as RLU normalized to total protein. Transduction is expressed as
a percentage of control (HAdV-5 transduction with serum-free medium alone); each experiment was performed in technical
quadruplicate and repeated two independent times. Mean±SE; *P<0.05. (b) Effect of neutralizing sera on HepG2 cell trans-
duction following incubation with 1000 vp HAdV cell 1 vectors in the presence of 1 IU ml 1 FX and 2.5% sera from patients
previously screened for anti-HAdV-5 Nabs (Parker et al., 2009) and stained for b-Gal expression 48 h post-transduction.
The experiment was performed four times; data are presented as mean±SE, and represent the percentage change relative to
serum control.
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5T*HVR7R (Fig. 2d, f). Increased binding to A549 cells was
observed following peptide insertion in the fibre HI loop,
although this did not correlate with increased transgene
expression (Fig. 2b, e). In HSV VSMCs, no increase in
binding was observed for the HAdV-5T*HI loop; however,
transduction was increased (Fig. 2f). This inconsistency
could be due to differences in the ability of the virus to
internalize and traffic through different cellular compart-
ments following uptake. The discrepancy is observed across
all of the cell types tested (SKOV3, A549 and HSV VSMC),
indicating that the insertion of RGD-4C in the fibre HI loop
may influence the surrounding capsid structure and hence
affect trafficking to the nucleus. Further studies are required
to fully delineate this finding.
FX binding HAdV-5 has been shown to prevent IgM- and
complement-mediated neutralization of the virus in vivo (Xu
et al., 2013), with inhibitory serum components’ binding sites
within the HAdV-5 HVRs (1–3 and 5–7) (Ma et al., 2015). We
tested if this response was altered by the insertion of the RGD-
4C peptide within these regions by investigating the sensitivity
of the vectors to murine serum in vitro using a snake venom-
derived FX-binding protein (X-bp), which binds to the Gla
domain of FX, preventing its interaction with the Ad hexon
(Waddington et al., 2008; Atoda et al., 1998). Recombinant Ad
vectors (21010 vpml 1) were incubated with RPMI-1640
medium, 90% C57BL/6 mouse serum or 90% C57BL/6
mouse serum pre-incubated with 40 µgml 1 X-bp, for 30min
at 37

C. Ad vector suspensions were diluted 200-fold in
serum-free medium and 100 µl was added to SKOV3 cells for
2 h at 37

C before being replaced with RPMI-1640 medium
with 2% FCS. Transgene expression was quantified 16 h post-
transduction as relative light units (RLU) normalized to total
protein. HAdV-5-mediated transduction significantly
increased in the presence of serum, and reduced following
pre-incubation of serum with X-bp (to bind and neutralize
FX) (Waddington et al., 2008; Mizuno et al., 2001).
HAdV-5T* demonstrated reduced transduction in the pres-
ence of murine serum compared with medium alone (Fig. 3a).
Peptide insertion failed to prevent virus neutralization and
reduction in transduction, indicating that these sites are not
critical to natural antibody-mediated binding and neutraliza-
tion (Fig. 3a). To evaluate what effect, if any, peptide insertion
might have on evasion of pre-existing human anti-HAdV-5
immunity, we performed neutralization assays on HepG2
cell transduction following incubation with 1000 vp HAdV
cell 1 in the presence of 1 IU ml 1 FX and in 2.5% serum iso-
lated from 103 cardiovascular patients (Parker et al., 2009).
Reporter gene expression was quantified 48 h post-transduc-
tion, and the changes in transduction relative to vector in the
absence of serum were assessed (Fig. 3b). Incorporation of
RGD-4C peptide into hexon or fibre had no discernible effect
on evasion of pre-existing immunity, with 39.6% evasion
observed at the 90% neutralization level for both HAdV-
5T*HVR7R and HAdV-5T*HI loop compared with 35.9%
for the parental HAdV-5T* (Fig. 3b).
This study successfully retargeted an FX-ablated HAdV-5
vector to human smooth muscle cells and demonstrated
that incorporation of the RGD-4C-targeting peptide does
not affect neutralization by natural antibodies in murine
sera or recognition by pre-existing anti-HAdV-5 immunity
in the general population. Whilst ablation of FX interactions
increases neutralization of Ad via IgM and complement, this
has only been demonstrated in murine models to date (Xu
et al., 2013). It remains unclear whether this is replicated in
humans and this will be important to determine in the
future. For intravascular delivery applications in humans,
optimized retargeting strategies, including those based upon
FX-binding-ablated Ad vectors described herein, will be of
key importance. Further studies will be required to evaluate
these vectors in an ex vivo human vein culture model
(Soyombo et al., 1990) and suitable in vivo animal models to
confirm the ability of these modified viruses to target to vas-
culature using clinically relevant model systems.
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